Using Mirabegron to Increase BP in Patients With POTS

Ki vehet részt

• Provision of signed and dated informed consent form
• Age > 18 years old
• Documented history of chronic (> 3 months) of orthostatic intolerance
• Diagnosis of syncope or pre-syncope and documented intermittent hypotension unresponsive to conventional life-style modification therapy; A history of syncope (complete loss of consciousness) or presyncope (the sensation that one is about to pass out); At least one documented hypotensive episode with systolic BP < 90 mmHg on 24-hr ABPM; Inadequate response to conventional therapies

Ki nem vehet részt

• Any experimental medication concomitantly or within 4 weeks of participation in the study
• Patients with other potential etiologies of syncope; Sustained tachyarrhythmias other than sinus tachycardia. Specifically, patients with a diagnosis of atrial fibrillation, sustained (> 30 seconds) arrhythmias including paroxysmal supraventricular tachycardia, atrial flutter, ventricular tachycardia, ventricular fibrillation; Symptomatic bradycardia before pacemaker implantation
• Wolff Parkinson-White Syndrome
• Stroke within the past 6 months
• Any history of myocardial infarction
• People with a history of allergy to ECG electrodes or adhesive tape
• Patients with known contraindications or precautions to mirabegron; Hypertension; Severe renal impairment (calculated CrCl < 30ml/min); Hepatic disease (Child-Pugh Class B); Pregnant or lactation; Geriatric patients in long term care facilities; Patients who are known to be allergic to mirabegron; Patients taking drugs that are CYP2D6 substrates, such as midodrine. An extensive list can be found at the following website: https://drug-interactions.medicine.iu.edu/MainTable.aspx
• Heart failure with either preserved or reduced ejection fraction
• Patients < 18 years old because mirabegron is not approved by FDA for use in children
• Active thyrotoxicosis
• Prisoners